Avo In R/R And Previously Untreated MCL

NCT04855695 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma
Refractory Lymphoma

Interventions

DRUG: Acalabrutinib
DRUG: Venetoclax
DRUG: Obinutuzumab

Sponsor

Austin I Kim

Collaborators

Roche-Genentech
AstraZeneca